Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued to investors on Saturday, Wall Street Zen reports.
Other equities analysts also recently issued reports about the stock. Morgan Stanley reduced their price objective on shares of Recursion Pharmaceuticals from $5.90 to $5.60 and set an "equal weight" rating for the company in a research note on Wednesday. JPMorgan Chase & Co. lowered their target price on Recursion Pharmaceuticals from $10.00 to $7.00 and set an "overweight" rating on the stock in a research report on Monday, November 16th. Needham & Company LLC reiterated a "buy" rating and set a $8.00 target price on shares of Recursion Pharmaceuticals in a report on Monday, October 19th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Recursion Pharmaceuticals in a report on Thursday, October 15th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Recursion Pharmaceuticals presently has a consensus rating of "Hold" and a consensus target price of $7.52.
Check Out Our Latest Research Report on RXRX
Recursion Pharmaceuticals Trading Down 10.1%
Shares of RXRX opened at $2.44 on Friday. Recursion Pharmaceuticals has a 12 month low of $2.44 and a 12 month high of $5.24. The firm has a fifty day simple moving average of $3.72 and a 200 day simple moving average of $3.45. The stock has a market capitalization of $1.52 billion, a price-to-earnings ratio of -2.72 and a beta of 1.15.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its earnings results on Monday, November 2nd. The company reported ($0.22) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.22). Recursion Pharmaceuticals had a negative net margin of 697.15% and a negative return on equity of 47.85%. The business had revenue of $18.55 million during the quarter, compared to the consensus estimate of $14.81 million. During the same quarter last year, the firm earned ($0.36) earnings per share. As a group, research analysts predict that Recursion Pharmaceuticals will post -0.89 earnings per share for the current fiscal year.
Insider Buying and Selling
In other Recursion Pharmaceuticals news, CEO Najat Khan sold 22,408 shares of the stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $3.52, for a total value of $78,876.16. Following the completion of the sale, the chief executive officer owned 2,072,890 shares in the company, valued at $7,296,572.80. This trade represents a 1.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Blake Borgeson sold 50,000 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, October 6th. The shares were sold at an average price of $4.84, for a total transaction of $242,000.00. Following the completion of the transaction, the director directly owned 6,108,287 shares of the company's stock, valued at approximately $29,564,109.08. This trade represents a 0.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 167,408 shares of company stock worth $701,276. Insiders own 6.65% of the company's stock.
Institutional Investors Weigh In On Recursion Pharmaceuticals
A number of institutional investors and hedge funds have recently modified their holdings of the company. American Century Companies Inc. grew its holdings in Recursion Pharmaceuticals by 46.0% during the third quarter. American Century Companies Inc. now owns 593,856 shares of the company's stock worth $2,453,000 after purchasing an additional 187,082 shares during the period. PCM Encore LLC acquired a new position in Recursion Pharmaceuticals during the third quarter worth approximately $98,000. Liontrust Investment Partners LLP acquired a new position in Recursion Pharmaceuticals during the third quarter worth approximately $375,000. Jump Financial LLC increased its position in Recursion Pharmaceuticals by 145.0% during the third quarter. Jump Financial LLC now owns 2,497,200 shares of the company's stock worth $10,313,000 after buying an additional 1,478,027 shares during the last quarter. Finally, First Trust Advisors LP raised its stake in Recursion Pharmaceuticals by 16.8% in the third quarter. First Trust Advisors LP now owns 3,551,885 shares of the company's stock valued at $14,669,000 after buying an additional 510,056 shares during the period. 89.06% of the stock is owned by institutional investors.
Recursion Pharmaceuticals Company Profile
(
Get Free Report)
Recursion Pharmaceuticals, Inc. is a biotechnology company that uses automation, large-scale biological and chemical data, and machine learning to discover and develop medicines. Its platform, known as Recursion OS, is designed to identify relationships between biological processes and potential treatments. The company develops drug candidates for areas including rare diseases and oncology, and it also works with pharmaceutical partners on drug discovery and development. Its research combines laboratory experiments with computational analysis to evaluate potential therapeutic targets and compounds.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Recursion Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.
While Recursion Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.